The clinical trial involving the small molecule inhibitor RRX-001 on small cell lung cancer (SCLC) exhibited a reduction in SIRPα expression on macrophages and CD47 expression, resulting in potent antitumor activity and hypotoxicity [121]. Here, SIRPA is linked to small cell lung carcinoma.